Sodium Fluoride F 18
Sodium Fluoride F-18
Kreitchman Pet Center
Human Prescription Drug
NDC 62072-500Sodium Fluoride F 18 also known as Sodium Fluoride F-18 is a human prescription drug labeled by 'Kreitchman Pet Center'. National Drug Code (NDC) number for Sodium Fluoride F 18 is 62072-500. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Sodium Fluoride F 18 drug includes Sodium Fluoride F-18 - 200 mCi/mL . The currest status of Sodium Fluoride F 18 drug is Active.
Drug Information:
| Drug NDC: | 62072-500 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Sodium Fluoride F 18 |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Proprietary Name Base: | Sodium Fluoride |
| The base of the Brand/Proprietary name excluding its suffix. |
| Proprietary Name Suffix: | F 18 |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Sodium Fluoride F-18 |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Kreitchman Pet Center |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Injection |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SODIUM FLUORIDE F-18 - 200 mCi/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | INTRAVENOUS
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | ANDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 23 May, 2016 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 27 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | ANDA203936 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Kreitchman PET Center
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 9L75099X6R
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class: | Radioactive Diagnostic Agent [EPC] Radiopharmaceutical Activity [MoA]
|
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 62072-500-30 | 30 mL in 1 VIAL, MULTI-DOSE (62072-500-30) | 23 May, 2016 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Sodium fluoride f 18 sodium fluoride f-18 sodium fluoride f-18 fluoride ion f-18 sodium chloride
Dosage Forms and Strength:
3 dosage forms and strengths multiple-dose vial containing 370-7,400 mbq/ml ( 10â200 mci/ml)at eos reference time of no-carrier-added sodium fluoride f18 in aqueous 0.9% sodium chloride solution. sodium fluoride f 18 injection is a clear, colorless, sterile, pyrogen-free and preservative-free solution for intravenous administration. multiple-dose vial containing 370-7,400 mbq/ml ( 10â200 mci/ml) at eos reference time of no-carrier-added sodium fluoride f18 in aqueous 0.9% sodium chloride solution (3) . sodium fluoride f 18 injection is a clear, colorless, sterile, pyrogen-free and preservative-free solution for intravenous administration.
Adverse Reactions:
6 adverse reactions no adverse reactions have been reported for sodium fluoride f 18 injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems. however, the completeness of these sources is not known. no adverse reactions have been reported for sodium fluoride f 18 injection based on a review of the published literature, publicly available reference sources, and adverse drug reaction reporting systems (6) . to report suspected adverse reactions, contact kreitchman pet center at 1-212-305-0081 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.
Description:
11 description 11.1 chemical characteristics sodium fluoride f 18 injection is a positron emitting radiopharmaceutical, containing no-carrier-added, radioactive fluoride f18 that is used for diagnostic purposes in conjunction with pet imaging. it is administered by intravenous injection. the active ingredient, sodium fluoride f18, has the molecular formula na[18f] with a molecular weight of 40.99, and has the following chemical structure: na +18 f - sodium fluoride f 18 injection is provided as a ready-to-use, isotonic, sterile, pyrogen-free, preservative-free, clear and colorless solution. each ml of the solution contains between 370 mbq to 7,400 mbq (10 mci to 200 mci) sodium fluoride f18, at the eos reference time, in 0.9% aqueous sodium chloride. the ph of the solution is between 4.5 and 8. the solution is presented in 30 ml multiple- dose glass vials with variable total volume and total radioactivity in each vial. 11.2 physical characteristics fluoride f18 decays by positron (β+) emission and has a half-life of 109.7 minutes. ninety-seven percent of the decay results in emission of a positron with a maximum energy of 633 kev and 3% of the decay results in electron capture with subsequent emission of characteristic x-rays of oxygen. the principal photons useful for diagnostic imaging are the 511 kev gamma photons, resulting from the interaction of the emitted positron with an electron (table 2). fluorine f18 atom decays to stable 18 o-oxygen. table 2: principal emission data for fluoride f18 radiation/emission % per disintegration mean energy positron (β+) 96.73 249.8 kev gamma (±) produced by positron annihilation [3] kocher, d.c. radioactive decay data tables doe/tic-11026, 69, 1981. 193.46 511.0 kev the specific gamma ray constant (point source air kerma coefficient) for fluoride f18 is 5.7 r/hr/mci (1.35 x 10 -6 gy/hr/kbq) at 1 cm. the half-value layer (hvl) for the 511 kev photons is 4 mm lead (pb). a range of values for the attenuation of radiation results from the interposition of various thickness of pb. the range of attenuation coefficients for this radionuclide is shown in table 3. for example, the interposition of an 8 mm thickness of pb with a coefficient of attenuation of 0.25 will decrease the external radiation by 75%. table 3:radiation attenuation of 511 kev photons by lead (pb) shielding shield thickness (pb) mm coefficient of attenuation 0 0.00 4 0.50 8 0.25 13 0.10 26 0.01 39 0.001 52 0.0001 table 4 lists the fraction of radioactivity remaining at selected time intervals from the calibration time. this information may be used to correct for physical decay of the radionuclide. table 4: physical decay chart for fluoride f18 time since calibration fraction remaining 0 calibration time 1.00 15 minutes 0.909 30 minutes 0.826 60 minutes 0.683 110 minutes 0.500 220 minutes 0.250 440 minutes 0.060 12 hours 0.011 24 hours 0.0001
How Supplied:
16 how supplied sodium fluoride f 18 injection is supplied in a multiple-dose type i glass vial with (elastomeric) stopper and aluminum crimp seal containing between 370-7,400 mbq/ml (10 to 200 mci/ml) of no-carrier-added sodium fluoride f18, at the eos reference time, in aqueous 0.9% sodium chloride solution. the total volume and total radioactivity per vial are variable. each vial is enclosed in a shielding container of appropriate thickness. the product is available in a 30 ml vial configuration with a variable fill volume. the ndc number is: 62702-500-30 (30 ml) storage store at 25°c (77°f); excursions permitted to 15â30°c (59â86°f). use the solution within 8 hours of the eos reference time. handling receipt, transfer, handling, possession, or use of this product is subject to the radioactive material regulations and licensing requirements of the u.s. nuclear regulatory commission, agreement states or licensing states as appropriate.